Modulation by LL-37 of the Responses of Salivary Glands to Purinergic Agonists

Stéphanie Pochet, Séverine Tandel, Stéphanie Querrière, Marie Tre-Hardy, Mikel Garcia-Marcos, Manuela De Lorenzi, Michel Vandenbranden, Aida Marino, Michel Devilleeschouwer, and Jean-Paul Dehaye

Laboratoires de Biochimie et de Biologie Cellulaire (S.P., S.T., S.Q., M.D.L., J.-P.D.) and Microbiologie, Institute of Pharmacy, Université libre de Bruxelles, Brussels, Belgium (M.T.-H., M.D.); Unité de Recherche sur la Structure et la Fonction des Membranes Biologiques, Faculty of Sciences, Université libre de Bruxelles, Brussels, Belgium (M.V.); and Departamento de Bioquimica y Biologia Molecular, Facultad de Ciencias, Universidad del Pais Vasco, Bilbao, Spain (M.G.-M., A.M.)

Received December 7, 2005; accepted March 1, 2006

ABSTRACT

The interaction of mice submandibular gland cells with LL-37 (LLGDFRKSKEKIGKFKRIVQRIKDFLRNLVPRTES), a cationic peptide with immunomodulatory properties, was investigated. LL-37 at a concentration that did not affect the integrity of the cells increased the uptake of calcium and activated a calcium-insensitive phospholipase A2 (PLA2). The small release of ATP induced by LL-37 could not account for this stimulation because apyrase did not significantly block the response to LL-37. The divergent cation magnesium inhibited the response to LL-37, but this inhibition was probably nonspecific because it also inhibited the in vitro bacteriostatic effect of the peptide. The increase of calcium uptake by LL-37 was not affected by 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN-62), a rather specific inhibitor of P2X7 receptors in mice. LL-37 also increased [Ca2+]i in cells from mice invalidated for these receptors. LL-37 had no effect on the response to carbachol. It inhibited the increase of [Ca2+]i and the activation of phospholipase D by ATP. It potentiated the activation of the PLA2 by the nucleotide. Finally, LL-37 increased the fluidity of the plasma membrane of submandibular gland cells. In conclusion, our results suggest that LL-37 is an autocrine regulator of submandibular gland cells. It does not stimulate mouse P2X7 receptors but modulates their responses.

Cathelicidins are proteins involved in the first phases of our defenses against pathogens. Their isolation relied on the analogy of their N-terminal proregions with cathelin, an inhibitor of cathepsin L originally isolated from bovine leukocytes (Ritonja et al., 1989). This highly conserved proregion (approximately 100 amino acids) shares many similarities with cystatins, inhibitors of the cysteine proteases. The C-terminal domain of cathelicidins varies among species both in terms of length (12–100 amino acids) and structure. The N- and C-terminal domains are separated by a sequence

This work was supported by grant 3.4506.00 from the Fonds de la Recherche Scientifique Médicale de Belgium and a grant from the Emile Defay Fund (to J.-P.D.) and by “Fundación benefico-docente Jesus Gangoiti-Barrera” and grants 9/UPV00042.310-15941/2004 from the University of the Basque (to A.M.) S.P. is a postdoctoral researcher of the Fonds National de la Recherche Scientifique of Belgium.

Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org. doi:10.1124/mol.105.021444.

ABBREVIATIONS: IL, interleukin; PLD, phospholipase D; PLA2, phospholipase A2; AM, acetoxymethyl ester; DPH, 1,6-diphenyl-1,3,5-hexatriene; BSA, bovine serum albumin; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; POPC, 1-palmitoyl, 2-oleyl-sn-glycero-3-phosphocholine; TLC, thin layer chromatography; HBS, HEPES-buffered saline; LDH, lactate dehydrogenase; PPI-PLC, polyphosphoinositide-specific phospholipase C; DMSO, dimethyl sulfoxide.
α-helix and the negative charges of the bacteria. The hydrophobic side of the helix has a detergent effect on the membrane of the bacteria.

LL-37 not only kills bacteria but also binds to endotoxin (Bartlett et al., 2004), is chemotactic for human peripheral blood neutrophils, monocytes, and T lymphocytes through formyl peptide receptor-like 1 receptor (Yang et al., 2000) and for mast cells through two other unknown receptors (Niyonsaba et al., 2002). In mast cells, it also promotes the release of histamine (Niyonsaba et al., 2001). It increases the release of chemokines from epithelial cells (Tjabringa et al., 2003) and promotes angiogenesis (Koczulla et al., 2003). It induces keratinocyte migration after epidermal growth factor receptor transactivation (Tokumaru et al., 2005). Binding sites for LL-37 have also been recently described in lung epithelial cells (Lau et al., 2005). It has been reported that LL-37 could mimic some of the responses to P2X 7 agonists by Pfizer, Inc. (Groton, CT) and obtained by homologous recombination (Solle et al., 2001). For those reasons, we decided to use a murine model and of mice with disrupted P2X7 gene (P2X7R−/− mice; Solle et al., 2001). Our results show that LL-37 could mimic some of the responses to P2X7 agonists [increase of the uptake of extracellular calcium and activation of phospholipase A2 (PLA2) activity]. LL-37 also modulated the responses to extracellular ATP: it inhibited the increase of [Ca2+]i, and the activation of phospholipase D (PLD), but it potentiated the activation of PLA2 in response to ATP. LL-37 also increased [Ca2+]i, in salivary glands from P2X7R−/− mice. LL-37 could thus elicit some cellular responses independently of P2X7 receptors but also modulated the responses coupled to these receptors.

Materials and Methods

Drugs and Animals. The experiments were carried out on male C57BL/6J control mice and on male P2X7R−/− mice kindly supplied by Pfizer, Inc. (Groton, CT) and obtained by homologous recombination (Solle et al., 2001). Breeding P2X7R−/− mice with females was used to maintain the colony of receptor-deficient animals. Mice used in the experiments were between 10 and 16 weeks of age. The animals were fed ad libitum and had free access to water. The care and use of the animals used in this study were approved by the Belgian Ministry of Agriculture in agreement with European regulations.

LL-37 (LLDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) was custom synthesized with 99% purity by Genemed Synthesis, Inc. (South San Francisco, CA). Two batches of LL-37 were used for these experiments. Fura-2/AM and 1,6-diphenyl-1,3,5-hexatriene (DPH) were from Invitrogen (Paisley, UK). Collagenase P and bovine serum albumin (BSA) fraction V were from Roche Diagnostics (Mannheim, Germany). The glutamine-free amino acids mixture was from Invitrogen. ATP, HEPES, leupetin, pepstatin A, aprotinin, phenylmethylsulfonyl fluoride, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and the ATP assay mix were obtained from Sigma-Aldrich (St. Louis, MO). Silicagel-coated thin layer chromatography (TLC) plates were from Merck (Darmstadt, Germany). Methanol, ethyl acetate, and chloroform were from Labscand Ltd. (Dublin, Ireland). The scintillation solution Ecoscent A was from National Diagnostics (Atlanta, GA).

Preparation of a Crude Cellular Suspension from Mouse Submandibular Glands. The mice were anesthetized and killed with ether. The submandibular glands were immediately dissected and finely minced. The minced tissue was digested in the presence of 0.4 to 0.5 U/ml collagenase P for 20 min at 37°C under constant shaking in 10 ml of HEPES-buffered saline (HBS) medium containing 24.5 mM HEPES, pH 7.4, 96 mM NaCl, 6 mM KCl, 1 mM MgCl2, 2.5 mM Na2PO4, 11.5 mM glucose, 5 mM sodium pyruvate, 5 mM sodium glutamate, 5 mM sodium fumarate, 1% (v/v) glucose, 0.125% (v/v) BSA. Ten minutes after the beginning of the digestion, the cells were aspirated five times with 10-, 5-, and 2-ml glass pipettes. At the end of the digestion, the crude suspension was mechanically dispersed by gentle pipetting, filtered and washed in an isotonic NaCl solution. The last pellet was resuspended in HBS medium and kept at 4°C until use.

Membrane Preparation. The cellular suspension from three mice was resuspended in 1 ml of ice-cold TEEI buffer (20 mM Tris-HCl, pH 8, 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 2.5 μg/ml oaptin, 2.5 μg/ml pepstatin A, and 2.5 μg/ml leupetin) and passed through a 27-gauge needle. The suspension was centrifuged at 1000g for 10 min at 4°C. The pellet was extracted with 1 ml of ice-cold TEEI buffer and centrifuged. This extraction was repeated three times. The four supernatants were pooled and centrifuged at 100,000g for 30 min at 4°C.

LDH Assay. LDH activity was measured in a spectrophotometer (Scandinavian Society for Clinical Chemistry and Clinical Physiolog., 1974). Two milliliters of Tris-EGTA-NADH (56 mM Tris, 5.6 mM KCl, 1 mM MgCl2, 2.5 mM Na2PO4, 11.5 mM glucose, 5 mM sodium pyruvate, 5 mM sodium glutamate, 5 mM sodium fumarate, 1% (v/v) glucose, 0.125% (v/v) BSA. Ten minutes after the beginning of the digestion, the cells were aspirated five times with 10-, 5-, and 2-ml glass pipettes. At the end of the digestion, the crude suspension was mechanically dispersed by gentle pipetting, filtered and washed in an isotonic NaCl solution. The last pellet was resuspended in HBS medium and kept at 4°C until use.

ATP Assay. The ATP present in the medium was estimated with a bioluminescent assay (Neufeld et al., 1975). Fifty microliters of the enzyme solution (cellular supernatant or whole-cell extract) was then added. Two minutes later, 200 μl of 14 mM sodium pyruvate was added. The disappearance of the NADH was monitored at 340 nm for 5 min at 37°C.

Measurement of [Ca2+]i. After its isolation, the crude pellet was resuspended in 6 ml of fresh HBS medium in the presence of mag-
nesium chloride, amino acids, and 0.1% albumin. The suspension was kept at 4°C until use. One milliliters of this suspension was incubated in 2 ml of HBS medium containing the presence of amino acids, 1 mM MgCl₂, 0.25 mM CaCl₂, and 0.5% (w/v) BSA. The suspension was incubated for 45 min at 25°C in the presence of 2 μM fura-2/AM. At the end of the incubation, 10 ml of isotonic NaCl was added to the tube, which was centrifuged for 1 min at 500g. The supernatant was discarded, and the pellet was resuspended in 4 ml of fresh HBS medium, in the absence of amino acids, magnesium chloride, or albumin but in the presence of 1 mM calcium chloride. Two milliliters of this suspension was transferred in the cuvette of a spectrofluorimeter and constantly agitated. The assay was performed at 25°C. The excitation wavelength was switched every second from 340 to 380 nm (slitwidth 8). The light emitted at 510 nm (slitwidth 16) was recorded. At the end of the assay, the traces were calibrated with the successive addition of 0.1 mM digitonin and 40 mM EGTA, pH 8.5 with Tris. The autofluorescence measured after quenching the fluorescence of the fura-2 by the addition of 100 mM MnCl₂ was subtracted from all the data before calculation of the ratios. The calcium concentration was estimated by the ratio method as described by Grynkiewicz et al. (1985).

Measurement of the Activity of PLA₂. Cells from three mice were resuspended in 1 ml of HBS medium containing the amino acids mixture, 1 mM CaCl₂, and 1 mM MgCl₂ without albumin. The cells were incubated for 2 h at 37°C in the presence of 5 μCi of [³H]oleic acid. At the end of this incubation, the cells were washed twice with 10 ml of isotonic NaCl. They were resuspended in 2 ml of HBS medium containing the amino acids mixture, 0.5 mM calcium chloride, 1 mM magnesium chloride, and 0.5% (w/v) BSA. They were incubated for 1 h at 37°C. At the end of this incubation, the cells were washed twice with 10 ml of isotonic NaCl. The cells were then resuspended in 9 ml of HBS containing the amino acids mixture, 0.5 mM calcium chloride, and 0.1% BSA, but no magnesium chloride. Aliquots of 0.5 ml were incubated for 10 min at 37°C either in control or in the tested condition. Each condition was tested in triplicate. At the end of the incubation, the cells were centrifuged, and 0.4 ml of the supernatant was transferred to scintillation vials. To estimate the amount of [³H]oleic acid present in the medium at the beginning of the incubation (blank values), a similar procedure was applied to nonincubated aliquots of cells. Aliquots of cells were also directly transferred to the scintillation vials to estimate the incorporation of the fatty acid in the cells (total counts). Three milliliters of Ecoscint A was added to each vial, and the radioactivity was measured in a beta-scintillation counter. The blank value was subtracted from all the results obtained with the incubated cells, and the results are expressed as percentage of the radioactivity incorporated in the cells.

Measurement of the Activity of PLD. The activity of PLD was assayed by measuring the formation of [³H]phosphatidyl ethanol, which is the product of its specific transphosphatidyl reaction in the presence of ethanol (Pochet et al., 2003). Cells from three mice were resuspended in 1 ml of HBS medium in the presence of 0.5 mM CaCl₂. They were incubated for 90 min at room temperature. The presence of colonies was examined after an overnight incubation. The number of experiments indicated. Statistical significance between various conditions was assessed with Student’s t test.
Results

LL-37 is generated by digestion of human cathelicidin by elastase or protease-3. The peptide has 37 amino acids with two leucines at its N-terminal side. With its five acidic and 11 basic residues, it is positively charged at physiological pH (pI = 10.6). It forms a perfect amphipathic α-helix between residues 11 and 31 (Agerberth et al., 1995). This peptide is highly toxic for bacteria but has also some deleterious effects on the plasma membrane of eukaryotic cells (Oren et al., 1999). In preliminary experiments, the release of LDH from a cellular suspension of submandibular glands exposed to LL-37 was examined (Fig. 1). After a 15-min incubation at 37°C, LL-37 did not promote the efflux of LDH when tested at concentrations up to 10 μM (from 1.8 ± 0.4% in the absence to 2.9 ± 0.5% in the presence of 10 μM LL-37; n = 3; P > 0.05). A higher concentration of LL-37 (20 μM) significantly increased the release of LDH after 15 min (to 11.5 ± 1.9%; P < 0.05; n = 3). After a 60-min incubation LL-37 significantly increased the release of LDH at 10 μM (to 7.9 ± 1.0%; P < 0.05) and at 20 μM (23.9 ± 3.1%; P < 0.01). The peptide was then tested at a 10 μM concentration on the hemolysis of murine red blood cells. After a 30-min incubation at 37°C, the hemolysis averaged only 2% of the maximal hemolysis measured with Triton X-100. It was thus decided to test the peptide at concentrations not exceeding 10 μM.

Effect of LL-37 on [Ca2+]i. Cells from submandibular glands were loaded with fura-2/AM. These cells were exposed to either carbachol (a muscarinic agonist activating a G protein) or ATP or LL-37 (Fig. 2, top). In response to 100 μM carbachol, [Ca2+]i sharply increased from a basal value of 127 ± 8 to 239 ± 21 nM (n = 4) 5 s after the addition of the agonist. This peak value was followed by a decrease and [Ca2+]i stabilized at a plateau of approximately 200 nM, significantly higher than the resting level. This response was typical of the response elicited by a receptor coupled to a G protein and activating a phospholipase C (PPI-PLC). The response to 1 mM ATP was very different. The [Ca2+]i, initially increased from 107 ± 14 to 263 ± 22 nM (n = 4) after 5 s and further increased for the next 3 min to reach 428 ± 40 nM (n = 4). This response was the consequence of the formation of a nonselective cation channel by the P2X7 receptor. Ten micromolar LL-37 increased [Ca2+]i, from 105 ± 6 to 152 ± 12 nM (n = 8) after 5 s and to 236 ± 20 nM after 3 min. The response to LL-37 was dose-dependent between 1 and 10 μM (Fig. 3).

In the absence of extracellular calcium, carbachol increased [Ca2+]i, from 27 ± 5 to 62 ± 8 nM (Fig. 4, inset; n =
LL-37 significantly decreased \([\text{Ca}^{2+}]_i\), from 57 ± 2 to 44 ± 3 nM after 90 s (n = 3; P < 0.05). After a preincubation for 2 min in control conditions and in the absence of calcium, the addition to the medium of 1 mM calcium significantly increased \([\text{Ca}^{2+}]_i\), to 165 ± 9 nM after 5 s and to 321 ± 30 nM (n = 4; P < 0.001) after 3 min. LL-37 (10 μM) also increased the uptake of extracellular calcium: \([\text{Ca}^{2+}]_i\), averaged 206 ± 26 nM after 5 s and remained stable (205 ± 30 nM after 3 min; n = 3; P < 0.01). From these results, it could be concluded that ATP and LL-37 did not mobilize intracellular pools of calcium but rather increased the uptake of extracellular calcium.

**Interaction between LL-37 and Muscarinic or Purinergic Agonists on \([\text{Ca}^{2+}]_i\).** The interaction between LL-37 and carbachol or ATP was next explored. The cells were exposed for 5 min to 10 μM LL-37 before stimulation with either 100 μM carbachol or 1 mM ATP. The preincubation with LL-37 had no effect on the response to carbachol (Fig. 5, top). The response to 1 mM ATP was inhibited by LL-37 (Fig. 5, bottom). In the absence of LL-37, the variation of \([\text{Ca}^{2+}]_i\) after 2-min exposure to the nucleotide averaged ±323 ± 38 nM.
nM (n = 6) in cells preincubated with DMSO and +198 ± 16 nM (n = 4) in cells preincubated with 10 μM LL-37 (P < 0.05).

**Contribution of ATP and Purinergic Receptors in the Response to LL-37.** The time course of the response to LL-37 and its dependence toward extracellular calcium suggested that an ionotropic purinergic receptor might be involved in the response to the peptide. Considering that cationic peptides can permeabilize the plasma membrane of eukaryotic cells (Oren et al., 1999), we considered the possibility that the response to LL-37 was merely the consequence of the release of ATP induced by the peptide. The cells were incubated with 10 μM LL-37. After centrifugation, the ATP content of the medium was estimated with a luciferin-luciferase mixture (Neufeld et al., 1975). Cells were incubated in a test tube in the chamber of the luminometer and preincubated with the ATP assay mix before the addition of LL-37 (Fig. 6). In these conditions, a significant increase (P = 0.015; n = 6) of the light emitted was noted. This increase was transient and significantly lower 15 s after the addition of the peptide (P = 0.029; n = 6). The contribution of this small release of ATP in the response to a lower (3 μM) concentration of LL-37 was examined in the presence of apyrase or magnesium ion. Apyrase is an ATP diphosphohydrolase that catalyzes the degradation of ATP; magnesium ion forms a complex with ATP and decreases the concentration of ATP4−, the true agonist of P2X receptors. Apyrase had no effect on the increase of [Ca2+]i, in response to carbachol (data not shown). The enzyme did not significantly affect the acute response to 300 μM ATP (Fig. 7, top) but fully suppressed its late effect [from +118 ± 9 nM (n = 4) in the absence of apyrase to +34 ± 4 nM (n = 5) in the presence of the enzyme, 4 min after the addition of ATP; P < 0.0001, nonpaired t test]. The response to 3 μM LL-37 was not inhibited by the enzyme [from +89 ± 19 nM (n = 5) in the absence to +56 ± 15 nM (n = 4) in the presence of 5 U/ml apyrase, after a 4-min exposure to LL-37; P = 0.2574] (Fig. 7, bottom). As shown in Fig. 8, the addition of 5 mM magnesium to the extracellular medium inhibited by more than 80% the response to 1 mM ATP (from +148 ± 17, n = 8 to +27 ± 4 nM, n = 7; P < 0.0001) and by 50% the response to LL-37 [from +81 ± 7 nM (n = 3) to +37 ± 14 nM (n = 3); P = 0.048]. Because the results obtained with apyrase and magnesium were not consistent, we decided to test the effect of magnesium on the "bactericidal" activity of LL-37. Five millimolar magnesium blocked the bacteriostatic and bactericidal effects of LL-37 (data not shown), confirming that magnesium inhibited the peptide itself. From these results and considering that apyrase did not inhibit the increase of [Ca2+]i, in response to LL-37, we concluded that released ATP did not mediate the effect of LL-37 on calcium.

It has been recently reported that LL-37 could activate by itself human P2X7 receptors (Elssner et al., 2004). We thus tested the effect of KN-62, a calmidazolium derivative that is a strong inhibitor of some P2X7 receptors (Virgino et al., 1997). Fig. 9, top, shows that 10 μM KN-62 inhibited the response to 1 mM ATP by 50% (from +130 ± 23 nM 2 min

---

**Fig. 6.** Effect of LL-37 on the release of ATP. Cells from submandibular glands were resuspended in a medium without calcium. Aliquots (190 μl) were transferred to a test tube containing 10 μl of the ATP assay mix. The test tube was placed in the chamber of the luminometer, and the light emitted was integrated for 15 s (−15 → 0). Ten microliters of DMSO or LL-37 (final concentration 10 μM) was added, and the light was measured for the next 30 s (0 → +15 and +15 → +30). Results are the means ± S.E.M. of six experiments. *, P < 0.05.

**Fig. 7.** Effect of apyrase on the variation of [Ca2+]i, in response to ATP or LL-37. Cells from submandibular glands loaded with fura-2 were resuspended in the presence of 1 mM CaCl2, in the absence (open symbols) or in the presence (closed symbols) of 5 U/ml apyrase. One minute after the start of the measurement, the cells were exposed to 300 μM ATP (top) or 3 μM LL-37 (bottom). Results are expressed as the variation of [Ca2+]i, compared with the initial [Ca2+]i. They are the means ± S.E.M. of four or five experiments.
after ATP in control cells to +65 ± 7 nM in cells treated with KN-62; n = 4; P = 0.038). KN-62 had no significant effect on the response to LL-37 (Fig. 9). These results suggested that the P2X7 receptors were probably not involved in the increase of [Ca²⁺]i in response to LL-37. This was confirmed using cells isolated from salivary glands of P2X7R-/− mice (Solle et al., 2001). Fig. 2, bottom, shows that these cells responded normally to carbachol. Their response to extracellular ATP was deeply blunted and had a totally different time course compared with cells from wild-type animals. ATP only transiently increased [Ca²⁺]i from 99 ± 6 to 125 ± 8 nM (n = 3). The variation of [Ca²⁺]i in response to LL-37 was not affected by the absence of P2X7 receptors (from 92 ± 2 to 233 ± 14 nM; n = 7).

Effect of LL-37 on the Activity of Phospholipases and on the Fluidity of the Plasma Membrane. The P2X7 receptor regulates the activity of various phospholipases in salivary glands (Alzola et al., 1998; Puchet et al., 2003). The activity of PLD was estimated by measuring the production of PETHER in cells labeled with [³H]oleic acid and incubated in the presence of ethanol. Fig. 10, top, shows that the purinergic agonist and carbachol increased the production of PETHER 3.5- and 2-fold, respectively. By itself, 10 μM LL-37 had no effect on the concentration of this phospholipid (90 ± 5%; n = 5 compared with control). LL-37 inhibited the activation of PLD by ATP from 348 ± 16% (n = 4) in the absence to 196 ± 16% (n = 4) in the presence of LL-37. The peptide had no effect on the stimulation of PLD by carbachol (Fig. 10, top).

To measure the activity of PLA2, the cells were labeled with [³H]oleic acid and after a washout period, the release of the fatty acid in the medium was estimated. Fig. 10, bottom, shows that carbachol had no significant effect on this activity. Extracellular ATP increased the release of oleic acid 2.5-fold. Removal of the extracellular calcium had no effect on the basal release of oleic acid, but it inhibited by 60% (from +170 to +70%) the stimulation by ATP. LL-37 also promoted the release of oleic acid. In the presence of extracellular calcium the response to 10 μM LL-37 was very sim-
ilar to the response to ATP. Removal of calcium had no effect on the response to LL-37 [from $7.1 \pm 0.8\%$ ($n = 5$) in the presence of calcium to $7.4 \pm 0.5\%$ ($n = 4$) in the absence of the ion]. The combination of the two stimuli further increased the release of oleic acid. The synergism was better observed in the absence of calcium: more than $15\%$ of the total oleic acid incorporated in the lipids was released when ATP and LL-37 were added together. Activation of the muscarinic receptors did not affect the release of oleic acid either in basal conditions or in the presence of LL-37. The effect of LL-37 on the fluidity of the plasma membrane was next tested. Membranes were isolated and incubated with a fluorescent probe (DPH). The movement of the probe was estimated by measuring the anisotropy at various temperatures in control membranes or in membranes preincubated with $10 \mu M$ LL-37. The anisotropy of micelles DPPC at $20^\circ C$ ($0.315 \pm 0.008$; $n = 3$) was much higher than the anisotropy of micelles of POPC ($0.117 \pm 0.009$; $n = 3$). The anisotropy decreased at higher temperatures in both micelles (data not shown). This result is consistent with the fact that the presence of an unsaturated fatty acid or a high temperature increases the fluidity of the micelles. By comparison, the anisotropy of control membranes was intermediate ($0.183 \pm 0.006$ at $20^\circ C$; $n = 6$). The pretreatment with LL-37 significantly decreased the anisotropy ($0.163 \pm 0.004$ at $20^\circ C$; $n = 6$, $P < 0.05$ compared with control membranes). This small effect was consistent in the six experiments and significant at every temperature tested.

**Discussion**

Our results show that in submandibular glands from control mice, LL-37 increased $[Ca^{2+}]_i$ and stimulated a calcium-insensitive PLA$_2$. These responses were observed at concentrations of LL-37 that had no effect on the response to carbachol. This last result confirmed that LL-37 did not affect the integrity of the muscarinic receptors, their coupling to a PPI-PLC, the filling state of intracellular pools of calcium, and their mobilization by inositol phosphates. LL-37 did not activate a receptor coupled to the activation of a PPI-PLC because LL-37 did not mobilize intracellular pools of calcium but only increased the uptake of extracellular calcium.

These responses to LL-37 were not secondary to the release of ATP. Indeed, the measurement of the ATP content in the incubation medium revealed that LL-37 evoked a very small and transient release of ATP. It must be stressed, however, that these measurements probably underestimate the concentration of ATP at the vicinity of the purinergic receptors. The contribution of ATP in the response to LL-37 was evaluated by the addition of apyrase in the incubation medium. This enzyme, which degrades ATP to AMP and pyrophosphate, strongly inhibited the response to exogenous ATP. It did not inhibit the response to LL-37. Similar results were obtained with cells incubated in the presence of glucose and hexokinase (data not shown). These results are not consistent with those of Elssner et al. (2004) who also reported that LL-37 could indeed provoke an efflux of ATP from lipopolysaccharide-primed monocytes but that apyrase inhibited the release of IL-1β by these cells in response to LL-37.

Because apyrase (and hexokinase) did not inhibit the response to LL-37 and because Elssner et al. (2004) reported that the peptide could stimulate P2X$_7$ receptors, the effect of KN-62, a rather specific antagonist of these receptors was tested on the response to LL-37. This calmidazolium derivative inhibited the response to ATP without affecting the response to LL-37. This is at variance with the results of Elssner et al. (2004) who reported that KN-62 could block the activation of macrophages by LL-37 and suggests that, in mouse salivary glands, the response to LL-37 was not mediated by P2X$_7$ receptors. Our results were confirmed in mice lacking the P2X$_7$ receptor. ATP only slightly increased $[Ca^{2+}]_i$ in cells from the salivary glands of these mice, and
this small response was strictly dependent on the presence of calcium in the medium, suggesting that it involved another P2X receptor (S. Pochet, personal communication). Cells from P2X,R−/− mice that were thus devoid of P2X receptors normally responded to LL-37 with respect to [Ca^{2+}]i. This result confirmed that the mouse P2X7 receptors were not required to observe an increase of [Ca^{2+}]i in response to LL-37.

It has been reported that LL-37 could increase [Ca^{2+}]i, in other cells such as mast cells (Niyonsaba et al., 2001) or neutrophils (Yang et al., 2000). In these systems, LL-37 activated a PPI-PLC and mobilized intracellular pools of calcium after activating a plasma membrane receptor coupled to a GTP-binding protein such as formyl peptide receptor-like 1 (Yang et al., 2000) or another receptor not yet defined (Niyonsaba et al., 2002). This mechanism is very unlikely in our model: LL-37 did not mobilize intracellular pools of calcium because it did not increase [Ca^{2+}]i, in a calcium-free medium. More recently, Tjabringa et al. (2003) reported that LL-37 could stimulate epidermal growth factor receptor in epithelial cells. This stimulation was blocked by G6001, an inhibitor of metalloproteases. They concluded that LL-37 might activate a metalloprotease and release an endogenous activator of EGFR. The response to LL-37 was not affected by either an activator or an inhibitor of the protease-activated receptor type 2, the protease-activated receptor expressed by the salivary glands (J. P. Dehaye, unpublished results), suggesting that this receptor was not involved in the response to LL-37. From all these negative results, it can be concluded that the uptake of calcium induced by LL-37 in mouse submandibular gland was not secondary to the activation of a murine purinergic- or protease-activated receptor or a receptor coupled to a G protein activating a PPI-PLC.

Salivary glands express various phospholipases A2 (Alzola et al., 1998) and D (Pochet et al., 2003) among which some are activated by an increase of [Ca^{2+}]i. Both ATP and LL-37 increased PLA2 activity. The activation of PLA2 by ATP is absent in cells from P2X,R−/− mice, confirming that P2X7 receptors are involved in this response (E. Kabré, personal communication). The response to LL-37 was not mediated by these receptors because it was present in cells from P2X,R−/− mice (E. Kabré, personal communication). The activation by LL-37 was not secondary to the increase of [Ca^{2+}]i, because it could still be observed in the absence of extracellular calcium. In these ionic conditions, the combination of ATP and LL-37 led to a much larger increase of the PLA2 activity. The effect of LL-37 on the activity of PLA2 has never been measured directly but it has been previously reported that LL-37, at the opposite of human defensin, did not promote the release of prostaglandins from mast cells (Niyonsaba et al., 2001). Yet the modulation of the PLA2 activity by amphipathic peptides is a well known phenomenon: mellitin, a strong activator of PLA2, shares with LL-37 a high content of basic residues and the formation of an amphipathic α-helix (Bucki et al., 2004). More recently it has been reported that antibacterial peptides with a high affinity for phosphatidyl cholines can activate a secretory PLA2 (Zhao and Kinnunen, 2003). LL-37 had no effect on the activity of the phospholipase D. This result was unexpected considering that other cationic antimicrobial peptides like mellitin or dermaseptin are activators of PLD, respectively, in human monocytic leukemia cells (Saini et al., 1999) and in polymorphonuclear leukocytes (Ammar et al., 1998). LL-37 specifically interfered with the purinergic regulation of PLD: it inhibited by nearly 50% the response to ATP without affecting the response to carbachol.

The previous results emphasized the fact that the interactions between LL-37 and purinergic responses were complex. By itself, LL-37 did not reproduce all the responses to ATP (it did not activate a PLD). When combined with ATP, LL-37 inhibited some responses (increase of [Ca^{2+}]i, and activation of PLD) but potentiated others (activation of PLA2). These contradictory effects of LL-37 on cellular responses induced by P2X7 receptors exclude a direct activation of the receptor by LL-37. The responses to LL-37 might be explained by the formation of a pore in the plasma membrane, and the subsequent influx of calcium and efflux of potassium responsible for the activation of a PLA2 (Andrei et al., 2004). The interaction of the peptide with the lipid phase of the plasma membrane might also account for its effects on the regulation by ATP of phospholipase A2 (activation) and PLD (inhibition). Indeed, according to Rao (1992), membrane-active peptides activate PLA2 and inhibit PLD activity when tested on unilamellar vesicles and these responses are best explained by a modification of the packaging of the lipid. It should be noted that LL-37 slightly increased the fluidity of the plasma membrane. LL-37 might thus regulate the cellular function by modifying the physicochemical state of the membrane rather than by interacting with a plasma membrane receptor. Zughaier et al. (2005) have proposed such a model. According to these authors, the synergy between endotoxin and LL-37 on the release of reactive oxygen species is mediated by a better interaction of the peptide with the plasma membrane and not by a direct interaction with TLR4, the receptor for lipopolysaccharides. This model is in agreement with the general model proposed by Perregaux et al. (2002) who proposed that the cationic peptides activate macrophages by perturbing their plasma membrane. It is also consistent with the recent results of Lau et al. (2006). These authors reported that concentrations of LL-37 similar to the concentrations used in our study could induce apoptotic lesions in thymocytes. We observed that LL-37 provoked a small release of ATP and a slight efflux of calcium when the cells were incubated in a calcium-free medium. A significant release of LDH was observed at high concentrations of LL-37. From these results, we cannot exclude that the responses of salivary glands to LL-37 were secondary to proapoptotic lesions provoked by the peptide.

In conclusion, our results show that LL-37 regulates the activity of submandibular gland cells. This result implies that salivary glands contribute to the host defense mechanisms not only by secreting LL-37 (Murakami et al., 2002; Woo et al., 2003) but also by the cellular responses like the activation of PL2 locally triggered by the peptide. The response of submandibular glands to LL-37 does not require the expression of P2X7 receptors, but the peptide can nevertheless modulate the responses to this receptor probably by its effect on the properties of the plasma membrane.

Acknowledgments

We thank Dr. C. Gabel (Pfizer, Inc.) for the generous gift of P2X,R−/− mice. The scintillation counter was a gift from Sorin Pharma (Brussels, Belgium).